probucol has been researched along with ST Elevation Myocardial Infarction in 1 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
ST Elevation Myocardial Infarction: A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "311 patients with STEMI were randomized to receive sirolimus- and probucol-eluting stents (n = 215) or zotarolimus-eluting stents (n = 96)." | 2.84 | Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. ( Byrne, RA; Cassese, S; Colleran, R; Giacoppo, D; Harada, Y; Ibrahim, T; Kastrati, A; Kufner, S; Lahmann, A; Laugwitz, KL; Lohaus, R; Repp, J; Schneider, S; Wiebe, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colleran, R | 1 |
| Kufner, S | 1 |
| Harada, Y | 1 |
| Giacoppo, D | 1 |
| Cassese, S | 1 |
| Repp, J | 1 |
| Wiebe, J | 1 |
| Lohaus, R | 1 |
| Lahmann, A | 1 |
| Schneider, S | 1 |
| Ibrahim, T | 1 |
| Laugwitz, KL | 1 |
| Kastrati, A | 1 |
| Byrne, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for probucol and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
Topics: Aged; Cardiovascular Agents; Coronary Thrombosis; Disease-Free Survival; Drug-Eluting Stents; Female | 2017 |